Roma Yumul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roma Yumul has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Christopher J. Hale
Seagen Inc., Bothell, Washington
55 shared publications - Lori Westendorf
Seagen Inc., Bothell, Washington
55 shared publications - Christopher Frantz
Seagen, Inc., Bothell, Washington. 1
36 shared publications - Esther S. Trueblood
Seagen Inc., Bothell, Washington
36 shared publications - Gabriela I. Patilea-Vrana
Department of Pharmaceutics, University of Washington, Seattle, Washington
36 shared publications - Jackie L. Stilwell
Seagen Inc., Bothell, Washington
36 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
H-Scores for integrin beta-6 across different cancer types
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
H-Scores for integrin beta-6 across different cancer types
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Antitumor activity in cell line-derived xenograft models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Antitumor activity in cell line-derived xenograft models
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Cell lines used in the characterization of SGN-B6A
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Cell lines used in the characterization of SGN-B6A
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Correlation of integrin beta-6 expression as assessed by RNA Seq or IHC in Champions NSCLC models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Correlation of integrin beta-6 expression as assessed by RNA Seq or IHC in Champions NSCLC models
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
2A2 antibody exhibits minimal blocking of integrin beta-6 binding to the latency-associated peptide (LAP) of tissue growth factor beta (TGF-β).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
2A2 antibody exhibits minimal blocking of integrin beta-6 binding to the latency-associated peptide (LAP) of tissue growth factor beta (TGF-β).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9B from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Growth curves of NSCLC PDX models grouped by histology
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9B from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Growth curves of NSCLC PDX models grouped by histology
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Pharmacokinetic parameters of SGN-B6A in cynomolgus monkeys
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Pharmacokinetic parameters of SGN-B6A in cynomolgus monkeys
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Evaluation of SGN-B6A effector function
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Evaluation of SGN-B6A effector function
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Pharmacokinetics of 6 mg/kg SGN-B6A in cynomolgus monkeys as assessed by total antibody ELISA (Tab) and antibody-conjugated MMAE (acMMAE, determined by quantitative mass spectrometry)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Pharmacokinetics of 6 mg/kg SGN-B6A in cynomolgus monkeys as assessed by total antibody ELISA (Tab) and antibody-conjugated MMAE (acMMAE, determined by quantitative mass spectrometry)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Legends for all supplementary figures in a single word file
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Legends for all supplementary figures in a single word file